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Glaucoma is the leading cause of irreversible blind-
ness in the world [1]. The disease can be characterized as a 
progressive optic neuropathy, where gradual visual field loss 
eventually leads to blindness. Primary open-angle glaucoma 
(POAG) is the most common type of glaucoma; it is typi-
cally asymptomatic at the early stages, and it is often not 
diagnosed until irreversible loss of the visual field transpires. 
Well-known risk factors are elevated intraocular pressure 
(IOP), advanced age, positive family history, and African 
ancestry [1]. The prevalence of glaucoma has been reported 
to be higher in black compared with white and mixed-race 
populations [2]. Similarly, the mean IOP was reported to be 
highest in black compared with mixed-race or white patients 
[3]. Currently, no reliable methods or biomarkers for the early 
detection of glaucoma are available.
In recent years, findings have suggested that serum 
25-OH vitamin D levels are associated with glaucoma. In 
a study on a South Korean population, participants with 
low serum 25-OH vitamin D levels were found to be at a 
significantly elevated risk of open-angle glaucoma (OAG) [4]. 
More recently, in a French case-control study, POAG cases 
had a lower mean serum 25-OH vitamin D concentration 
than controls did, as well as a greater prevalence of vitamin 
D insufficiency [5]. Past findings have also revealed asso-
ciations between vitamin D levels and various other ocular 
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Purpose: To study the relationship between primary open-angle glaucoma (POAG) in a cohort of patients of African 
descent (AD) and serum vitamin D levels.
Methods: A subset of the AD and glaucoma evaluation study III (ADAGES III) cohort, consisting of 357 patients with 
a diagnosis of POAG and 178 normal controls of self-reported AD, were included in this analysis. Demographic infor-
mation, family history, and blood samples were collected from all the participants. All the subjects underwent clinical 
evaluation, including visual field (VF) mean deviation (MD), central cornea thickness (CCT), intraocular pressure (IOP), 
and height and weight measurements. POAG patients were classified into early and advanced phenotypes based on the 
severity of their visual field damage, and they were matched for age, gender, and history of hypertension and diabetes. 
Serum 25-Hydroxy (25-OH) vitamin D levels were measured by enzyme-linked immunosorbent assay (ELISA). The 
association of serum vitamin D levels with the development and severity of POAG was tested by analysis of variance 
(ANOVA) and the paired t-test.
Results: The 178 early POAG subjects had a visual field MD of better than −4.0 dB, and the 179 advanced glaucoma 
subjects had a visual field MD of worse than −10 dB. The mean (95% confidence interval [CI]) levels of vitamin D of the 
subjects in the control (8.02 ± 6.19 pg/ml) and early phenotype (7.56 ± 5.74 pg/ml) groups were significantly or marginally 
significantly different from the levels observed in subjects with the advanced phenotype (6.35 ± 4.76 pg/ml; p = 0.0117 
and 0.0543, respectively). In contrast, the mean serum vitamin D level in controls was not significantly different from 
that of the subjects with the early glaucoma phenotype (p = 0.8508).
Conclusions: In this AD cohort, patients with advanced glaucoma had lower serum levels of vitamin D compared with 
early glaucoma and normal subjects.
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conditions. Serum 25-OH vitamin D deficiency was associ-
ated with a reduced ganglion cell complex in a cohort of older 
Caucasians [6]. Moreover, a lower serum 25-OH vitamin D 
concentration was associated with a high risk of myopia in 
a population of young adults in Australia [7]. In addition, a 
poorer quality of overall visual acuity was associated with 
vitamin D insufficiency in older adults [8]. Although the 
prevalence of glaucoma has been observed to be high in 
patients of African descent (AD), information is not avail-
able on the relationship between serum vitamin D levels and 
POAG in this population.
There is abundant evidence that, compared with Ameri-
cans with European ancestry, African Americans display 
significantly lower levels of 25-OH vitamin D. Lower serum 
levels of 25-OH vitamin D in African American women 
has been attributed to a reduction in dermal synthesis [9]. 
Contrasting health outcomes have been observed in these 
studies when comparing 25-OH vitamin D levels between 
white and African Americans. For example, higher serum 
levels of 25-OH vitamin D were associated with lower 
cardiovascular disease (CVD) risk in white Americans, while 
higher serum 25-OH vitamin D in black Americans was asso-
ciated with a slightly higher CVD risk. In addition, higher 
25-OH vitamin D levels were associated with lower all-cause 
mortality in white Americans, but they were less strongly 
associated with all-cause mortality in black Americans [10]. 
However, there is limited information on the effects of 25-OH 
vitamin D levels on ocular abnormalities in African Ameri-
cans. The aim of this study was investigating the possible 
association between vitamin D levels and the development 
of POAG, as well as the severity of POAG in a cohort of 
patients of AD.
METHODS
Subjects: A subset of 357 POAG patients and 178 control 
subjects of AD participating in the “Contribution of Geno-
type to Glaucoma phenotype in African Americans” study 
(Figure 1), commonly referred to as the AD and glaucoma 
evaluation study III (ADAGES III), were included in this 
study. The research was conducted following the tenets of 
the Declaration of Helsinki and with the approval of the 
institutional review boards of the participating institutions.
To be considered to have POAG, patients were required 
to have glaucomatous visual field damage or an optic disc 
photograph or clinical drawing clearly indicating POAG in 
their medical charts. Control subjects had IOP ≤ 21 mmHg, 
Figure 1. Sample selection scheme. 
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no evidence of glaucomatous optic neuropathy based on a 
clinical exam, and no family history of POAG in first-degree 
relatives. The exclusion criteria included the following: 1) 
ocular pathology making it difficult to determine whether 
there was characteristic visual field damage, 2) closed or 
occluded angles, 3) secondary glaucoma, 4) a history of 
human immunodeficiency virus or hepatitis C infection, and 
5) non-African or European descent.
For this report, POAG patients were classified into 
“early” and “advanced” phenotypes based on the severity of 
their visual field damage at the time of blood sample collec-
tion; early POAG patients had a visual field MD better than 
−4 dB, and advanced POAG had visual field MD values ≤ 
−10 dB. Glaucoma patients with visual field MD between −4 
and −10 dB were excluded. The three groups were matched 
for age, sex, and self-reported history of hypertension and 
diabetes.
Ocular measurements: Central corneal thickness (CCT), the 
mean deviation (MD) of the visual field closest to the blood 
draw, and the highest IOP recorded were extracted from each 
patient’s medical record. The mean values of both eyes were 
included in the analysis. IOP measurements were obtained 
using a Goldman Applanation Tonometer.
Body mass index: Each participant’s height and weight were 
measured, and the body mass index (BMI) was calculated 
according to standard protocols. Height and weight measure-
ments were performed at each study center using standardized 
protocols and equipment. A model 213 stadiometer (Seca, 
Chino, CA) was used to measure the height to the eighth of an 
inch. A Professional Remote Digital Scale (Health-o-Meter, 
McCook, IL) was used to measure weight after the removal 
of jackets or bulky sweaters, as described previously [11].
Measurement of 25-OH vitamin D in serum: The levels of free 
serum 25-OH vitamin D were measured by enzyme-linked 
immunosorbent assay (ELISA) using a Free 25OH Vitamin 
D ELISA kit (Future Diagnostics and DIAsource Immuno-
Assays, Louvain-la-Nueve, Belgium). The methodology used 
for the measurement of free vitamin D has been reported to 
be reliable in recent studies [12,13]. Free vitamin D has also 
been observed as being the biologically active form [14], and 
for these reasons, we chose to measure levels of free 25-OH 
vitamin D.
Statistical analysis of data: The means and standard devia-
tions (SDs) of serum vitamin D levels were calculated using 
standard methodology. A log transformation was applied to 
normalize the distribution, and analyses were performed on 
the log-transformed free vitamin D levels. Analyses of vari-
ance (ANOVAs) were used to compare the vitamin D levels 
among the three POAG groups, and a post hoc Tukey’s test 
was used for pairwise comparisons. We also compared the 
demographic data among the three groups, using ANOVA 
for continuous data (age, BMI, MD, IOP, CCT) and the chi-
square test for binary traits (gender, diabetes, hypertension) 
and categorical data (family history of glaucoma). To test the 
correlations between free vitamin D and the demographic 
data, we applied the Pearson correlation for continuous data 
(age, BMI, MD, IOP, CCT), t-test for binary data (gender, 
diabetes, hypertension), and ANOVA for categorical data 
(family history of glaucoma). Most of the quantitative traits 
in this study were normally distributed; the exception was the 
free vitamin D levels, which had a skewness level of 2.2973 
and kurtosis of 6.2872. Thus, we applied log transformation 
only to the free vitamin D levels (Appendix 1).
RESULTS
The demographic, clinical, and ocular characteristics of the 
early POAG, advanced POAG, and controls without POAG 
study groups are presented in Table 1. As patients were 
matched for age, sex, history of systemic hypertension, 
and diabetes, no significant differences were found in these 
characteristics. BMI was significantly lower in the advanced 
POAG patients compared with the controls and early POAG 
(p = 0.0334 and 0.0041). There were no significant differ-
ences between controls and early POAG regarding BMI (p 
= 0.7142). Most subjects had eye measurements performed 
on the same day as the blood draw. Specifically, the median 
(interquartile range) difference in years between the blood 
draw and 1) visual field testing and 2) IOP measurements 
was small, at 0.4 (1.1) years and 0.0 (0.1) years, respectively.
Advanced glaucoma patients had a significantly higher 
“highest IOP” recorded (p<0.0001), as well as worse visual 
field MD (p<0.0001); moreover, they were more likely to 
have a family history of glaucoma (p<0.0001) compared with 
the control group. Compared with the early POAG group, 
advanced glaucoma patients also had a significantly higher 
“highest IOP” record (p<0.0001) and worse visual field MD 
(p<0.0001; Table 1). There were no differences among the 
three groups in terms of CCT. Similarly, no significant differ-
ences were noted in self-reported hypertension and diabetes 
among the three groups.
Levels of serum 25 (OH) vitamin D in different groups and 
the relationship between vitamin D and progression of glau-
coma: The associations of age, visual field MD, and IOP 
with free vitamin D 19 were small but significantly different 
from zero (r = 0.1116, 0.1236, 0.0819 and p = 0.01094, 0.0162, 
0.0018, respectively). No linear correlations significantly 
different from zero were observed between free vitamin D 
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and CCT (r = 0.0377, p = 0.4744) or between free vitamin 
D and BMI (r = −0.0448, p = 0.333; Table 2). Females had 
significantly higher mean levels of free vitamin D than males 
did (7.90 ± 5.97 vs. 6.09 ± 4.62; p = 0.0002). No significant 
differences in free vitamin D levels were observed in cases 
versus controls in terms of diabetes (7.96 ± 6.18 in diabetics 
vs. 7.01 ± 5.33 in controls; p = 0.0886) or hypertension (7.52 
± 5.80 in hypertensives versus 6.93 ± 5.26 in controls; p = 
0.2724; Table 3).
The serum free vitamin D levels of the normal control 
group were in the range of 1.08–33.64 pg/ml, with a mean ± 
SD of 8.02 ± 6.19 pg/ml. The free vitamin D levels of patients 
in the early POAG group were in the range of 0.77–33.22 pg/
ml, with a mean ± SD of 7.56 ± 5.74 pg/ml. In contrast, the 
advanced glaucoma group of patients had lower serum free 
vitamin D levels, in the range of 0.59–31.47 pg/ml, with a 
mean ± SD of 6.35 ± 4.76 pg/ml (Table 4).
The ANOVA test revealed significant differences in the 
serum vitamin D levels among the three groups of subjects 
tested (p = 0.0098, Figure 2). In the follow-up analysis with 
the pairwise t-test, we found that both the normal and early 
(0 to −4) glaucoma groups were significantly or marginally 
significantly different from the advanced (worse than −10) 
glaucoma group (p = 0.0117 and 0.0543, respectively), while 
the normal group was not significantly different from the 
early (better than −4) glaucoma group (Figure 2). Similar 
results were observed when comparing the male subjects in 
the three groups (p = 0.0045), while no significant difference 
was observed within female subjects (p = 0.2986).
DISCUSSION
Vitamin D has attained much focus over the last couple of 
decades as an important contributor to health, especially 
in the context of chronic lifestyle-related diseases. Vitamin 
D deficiency has been associated with a wide range of 
Table 1. Demographic, clinical and ocular characteristics by study groups.
Information Trait
Control 
(n=178)
Early POAG 
(n=178)
Advanced POAG 
(n=179)
P 
value*
Demographic 
and clinical 
information
Age at blood draw (SD; 
MIN,MAX) 67.2 (9.09; 27.8, 95.5) 65.29 (10.47; 33.3, 92.4) 67.51 (11.28; 32.2, 91.4) 0.0934
Gender (% male) 32.6 32.6 33 0.9962
BMI (SD; MIN,MAX) 31.0 (6.7; 17.9, 54.5) 31.6 (6.3; 19.2, 54.4) 29.2 (6.3; 16.9, 49.4) 0.0039
Self-reported diabetes (%) 31.5 33.7 31.3 0.8615
Self-reported hypertension 
(%)
73 67.4 65.9 0.3217
Ocular 
Information
** −2.39 (3.99; −21.99, 1.2) −1.77 (1.47; −3.98, 1.85) −21.65 (6.53; −35.3, −10.1) <0.0001
Visual Field Mean Deviation in dB (SD; MIN,MAX)
Intraocular pressure in 
mmHg (SD; MIN,MAX) 15.9 (3.0; 8.5, 28.0) 19.7 (6.2; 9.5, 46.0) 22.7 (9.3; 8, 54.5) <0.0001
Central corneal thickness in 
um (SD; MIN,MAX) 531.3 (36.7; 450.0, 586.0) 538 (37.3; 445, 635.5) 532.4 (44.4; 330, 730) 0.3935
Family History of Glaucoma 
(1st degree relative; %) 8.4 36.2 49.6 <0.0001
* p value is the ANOVA across all 3 groups. ** Visual Field Mean was the criteria for selection, thus the significant difference is expected, 
#Note that the three groups have been matched on age, sex, self-reported history of diabetes and of hypertension. All 4 traits were not 
significant between groups by ANOVA.
Table 2. Correlations between Free Vitamin D and Age, MD, CCT, BMI, and IOP.
 N Correlation Coefficient P value
Age 519 0.1116 0.0109
MD 378 0.1236 0.0162
CCT 363 0.0377 0.4744
BMI 469 −0.0448 0.333
IOP 519 −0.0819 0.0018
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pathologies, including osteoporosis, CVD, diabetes, cancer, 
autoimmune diseases, and depression in several popula-
tions, including subjects of AD [12,15]. A strong association 
between vitamin D levels and various ophthalmic conditions, 
such as age-related macular degeneration, cataract, and dry 
eye syndrome has been reported [8]. Specifically, the associa-
tion of vitamin D levels with a risk of glaucoma has been 
reported in Chinese, Korean, French, and Caucasian popula-
tions [4-6,13].
In the present study on individuals of African descent, 
advanced glaucoma patients had significantly lower levels 
of serum vitamin D (p<0.01) than both the normal control 
and early glaucoma groups did. Our findings are consistent 
with a larger cross-sectional study on the South Korean 
population that included 290 OAG cases, 410 suspected 
glaucoma cases, and 5,394 controls [4]. That study reported 
a significantly elevated risk of OAG at lower vitamin D levels, 
supporting the association between glaucoma and vitamin D 
levels. Similarly, a French study found reduced vitamin D 
levels in 150 moderate and severe glaucoma patients (mean 
VF MD −17 db) compared to 164 controls [5]. However, that 
study did not find a difference in serum vitamin D levels 
between the 99 patients with severe POAG and the 51 with 
moderate POAG [5]. The variation observed in the asso-
ciation of vitamin D with severity of glaucoma between the 
current study and studies on other populations could be due 
to the difference in the severity of the two glaucoma groups 
included in the analysis. For example, in the current study, we 
compared vitamin D levels in early (better than −4 dB) and 
advanced POAG (worse than −10 dB), while the French study 
compared vitamin D levels in moderate (better than −12 dB) 
and advanced glaucoma (worse than −12 dB). In addition, the 
underlying genetic variation between the French population 
and patients of AD may also contribute to the differences 
observed. Analysis of a larger cohort of patients from both 
populations using a common set of diagnostic criteria may 
provide a better understanding of the association between 
serum vitamin D levels and glaucoma progression. Identi-
fication of genetic factors associated with glaucoma in these 
populations may provide further insight into the mechanism 
underlying the variation in findings between different 
populations.
It is intriguing to note that the vitamin D levels were 
not associated with the risk of POAG in our cohort, while 
a significant association was observed with advanced glau-
coma (Table 4). Little is known about the specific role of 
vitamin D in the pathology of glaucoma, and this remains to 
be elucidated. However, vitamin D deficiency is reported to 
be associated with other neurodegenerative diseases, such as 
Alzheimer disease [16,17]. Specifically, supplementation of 
vitamin D analogs was suggested to have beneficial effects 
in Alzheimer disease patients [18]. It is well established that 
Table 3. Correlation between Gender, Diabetes and Hypertension.
Trait N P value* Category N
Mean pg/
ml
Median 
pg/ml
Std Dev 
pg/ml
Minimum 
pg/ml
Gender 519 0.0002 Female 349 7.9 6.28 5.97 0.77
   Male 170 6.09 4.87 4.62 0.59
Diabetes 519 0.0886 No 355 7.01 5.63 5.33 0.59
   Yes 164 7.96 6.02 6.18 1.14
Hypertension 515 0.2724 No 163 6.93 5.43 5.26 0.59
   Yes 352 7.52 5.99 5.8 0.77
Family History 
Glaucoma 321 0.0041 No 214 6.99 5.44 5.05 0.59
   Yes 107 5.54 4.5 3.72 0.77
* t test p value
Table 4. Distribution of Serum Free Vitamin D levels in the three groups.
Study Group N
Mean 
pg/ml
SD 
pg/ml
Minimum 
pg/ml
Maximum 
pg/ml
Median 
pg/m
Lower Quartile 
pg/m
Upper Quartile 
pg/m
Control 174 8.02 6.19 1.08 33.64 6.29 3.97 9.76
Early 170 7.56 5.74 0.77 33.22 5.99 4.17 9.14
Advanced 175 6.35 4.76 0.59 31.47 5.09 3.47 7.19
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factors influencing inflammation contribute to the severity of 
neurodegeneration [19]. Studies on vitamin D have suggested 
that it has a key role in regulating the physiological processes 
involved in the inflammation and degeneration of neuronal 
tissue [20]. Therefore, it is likely that low levels of vitamin 
D may not result in development of glaucoma; however, the 
insufficiency of vitamin D may affect the severity of glau-
coma in patients as a result of increased inflammation and 
neurodegeneration [21]. The design of the current study does 
not provide information on the rate of glaucoma progression, 
and therefore, the effect of vitamin D status on the rate of 
progression is unknown. Gaining an in-depth understanding 
of the molecular mechanisms underlying glaucoma and the 
influence of vitamin D on disease pathology may provide 
insight into the pathophysiology of glaucoma and the effect of 
vitamin D insufficiency. Furthermore, as serum vitamin D is 
a modifiable factor, the findings of this study could be helpful 
in managing the severity of glaucoma by targeting vitamin D.
APPENDIX 1. A SCATTER PLOT SHOWING 
THE RELATIONSHIP BETWEEN DIFFERENT 
OCULAR AND CLINICAL TRAITS.
To access the data, click or select the words “Appendix 1.”
ACKNOWLEDGMENTS
Financial Support: National Eye Institute: EY023704, 
P30EY022589, EY110008, EY019869, EY021818, EY021237. 
Supported in part by the National Center for Advancing 
Translational Sciences, CTSI grant UL1TR001881, and the 
National Institute of Diabetes and Digestive and Kidney 
Disease Diabetes Research Center (DRC) grant DK063491 
to the Southern California Diabetes Endocrinology Research 
Center, Supported in part by Research to Prevent Blindness 
(New York, NY). Conflict of Interest: LMZ: Carl Zeiss 
Meditec, Heidelberg Engineering, Optovue Inc.,Topcon 
Medical System Inc. (financial support) CAG: National 
Eye Institute, EyeSight Foundation of Alabama, Research 
to Prevent Blindness, Carl Zeiss Meditec, Heidelberg Engi-
neering, SOLX (financial support) JML: Alcon, Allergan, 
Figure 2. Analysis of variance 
(ANOVA) analysis of serum free 
vitamin D levels in the three study 
groups. The y-axis gives the mean 
log free vitamin D levels in each 
of the three study groups. The p 
value on the right of the figure was 
obtained from the ANOVA test 
when comparing the three groups 
of subjects. On the top of the figure 
are p values for each pairwise 
comparison. 
Molecular Vision 2019; 25:438-445 <http://www.molvis.org/molvis/v25/438> © 2019 Molecular Vision 
444
Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, 
Reichert, Valeant Pharmaceuticals (Consultant); Bausch & 
Lomb, Carl Zeiss Meditec, Heidelberg Engineering, National 
Eye Institute, Optovue, Reichert, Topcon (financial support) 
RF: None FAM: Alcon, Allergan, Bauch + Lomb, Carl Zeiss 
Meditec, Heidelberg Engineering, Merck, Reichert, Sensimed 
and Topcon (financial support); Alcon, Allergan, Carl Zeiss 
Meditec, National Eye Institute, and Reichert (research 
support); Allergan, Carl Zeiss Meditec, Novartis (consultant) 
RNW: Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, 
Topcon (Consultant); Heidelberg Engineering, Carl Zeiss 
Meditec, Genentech, Optovue, Topcon (Financial support)
REFERENCES
1. Coleman AL, Brigatti L. The glaucomas.  Minerva Med  2001; 
92:365-79. [PMID: 11675580].
2. Leske MC, Connell AM, Schachat AP, Hyman L. The 
Barbados Eye Study. Prevalence of open angle glaucoma. 
Arch Ophthalmol  1994; 112:821-9. [PMID: 8002842].
3. Leske MC, Connell AM, Wu SY, Hyman L, Schachat AP. 
Distribution of intraocular pressure. The Barbados Eye Study. 
Arch Ophthalmol  1997; 115:1051-7. [PMID: 9258228].
4. Yoo TK, Oh E, Hong S. Is vitamin D status associated with 
open-angle glaucoma? A cross-sectional study from South 
Korea.  Public Health Nutr  2014; 17:833-43. [PMID: 
24476947].
5. Goncalves A, Milea D, Gohier P, Jallet G, Leruez S, Baskaran 
M, Aung T, Annweiler C. Serum vitamin D status is asso-
ciated with the presence but not the severity of primary 
open angle glaucoma.  Maturitas  2015; 81:470-4. [PMID: 
26059919].
6. Uro M, Beauchet O, Cherif M, Graffe A, Milea D, Annweiler 
C. Age-Related Vitamin D Deficiency Is Associated with 
Reduced Macular Ganglion Cell Complex: A Cross-Sectional 
High-Definition Optical Coherence Tomography Study. 
PLoS One  2015; 10:e0130879-[PMID: 26090872].
7. Yazar S, Hewitt AW, Black LJ, McKnight CM, Mountain JA, 
Sherwin JC, Oddy WH, Coroneo MT, Lucas RM, Mackey 
DA. Myopia is associated with lower vitamin D status in 
young adults.  Invest Ophthalmol Vis Sci  2014; 55:4552-9. 
[PMID: 24970253].
8. Beauchet O, Milea D, Graffe A, Fantino B, Annweiler C. 
Association between serum 25-hydroxyvitamin D concen-
trations and vision: a cross-sectional population-based study 
of older adults.  J Am Geriatr Soc  2011; 59:568-70. [PMID: 
21391957].
9. Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized controlled 
trial of vitamin D3 supplementation in African American 
women.  Arch Intern Med  2005; 165:1618-23. [PMID: 
16043680].
10. Brown LL, Cohen B, Tabor D, Zappala G, Maruvada P, 
Coates PM. The vitamin D paradox in Black Americans: a 
systems-based approach to investigating clinical practice, 
research, and public health - expert panel meeting report. 
BMC Proc  2018; 12:6-[PMID: 30044889].
11. Zangwill L, Ayyagari R, Liebmann JM, Girkin CA, Feldman 
R, Dubiner H, Dirkes KA, Holmann M, Williams-Steppe 
E, Hammel N, Saunders LJ, Vega S, Sandow K, Roll K, 
Slight R, Auerbach D, Samuels BC, Panarelli JF, Mitchell 
JP, Al-Aswad LA, Park SC, Tello C, Cotliar J, Bansal R, 
Sidoti PA, Cioffi GA, Blumberg D, Ritch R, Bell NP, Blieden 
LS, Davis G, Medeiros FA, Ng MCY, Das SK, Palmer ND, 
Divers J, Langefeld CD, Freedman BI, Bowden DW, Chris-
topher MA, Chen YI, Guo X, Taylor KD, Rotter JI, Weinreb 
RN. African Descent and Glaucoma Evaluation Study III 
Genomics Study Group.  Ophthalmology  2019; 126:156-70. 
[PMID: 29361356].
12. Wilkins CH, Birge SJ, Sheline YI, Morris JC. Vitamin D defi-
ciency is associated with worse cognitive performance and 
lower bone density in older African Americans.  J Natl Med 
Assoc  2009; 101:349-54. [PMID: 19397226].
13. Lv Y, Yao Q, Ma W, Liu H, Ji J, Li X. Associations of vitamin 
D deficiency and vitamin D receptor (Cdx-2, Fok I, Bsm I 
and Taq I) polymorphisms with the risk of primary open-
angle glaucoma.  BMC Ophthalmol  2016; 16:116-[PMID: 
27435453].
14. Tsuprykov O, Chen X, Hocher CF, Skoblo R, Lianghong Y, 
Hocher B. Why should we measure free 25(OH) vitamin 
D?  J Steroid Biochem Mol Biol  2018; 180:87-104. [PMID: 
29217467].
15. Holick MF. Vitamin D deficiency.  N Engl J Med  2007; 
357:266-81. [PMID: 17634462].
16. Perez-Lopez FR, Chedraui P, Fernandez-Alonso AM. 
Vitamin D and aging: beyond calcium and bone metabolism. 
Maturitas  2011; 69:27-36. [PMID: 21429678].
17. Amer M, Qayyum R. Relation between serum 25-hydroxyvi-
tamin D and C-reactive protein in asymptomatic adults (from 
the continuous National Health and Nutrition Examination 
Survey 2001 to 2006).  Am J Cardiol  2012; 109:226-30. 
[PMID: 21996139].
18. Grimm MOW, Thiel A, Lauer AA, Winkler J, Lehmann J, 
Regner L, Nelke C, Janitschke D, Benoist C, Streidenberger 
O, Stötzel H, Endres K, Herr C, Beisswenger C, Grimm 
HS, Bals R, Lammert F, Hartmann T. Vitamin D and Its 
Analogues Decrease Amyloid-beta (Abeta) Formation and 
Increase Abeta-Degradation.  Int J Mol Sci  2017; 18:18-
[PMID: 29257109].
19. Jiao KP, Li SM, Lv WY, Jv ML, He HY. Vitamin D3 repressed 
astrocyte activation following lipopolysaccharide stimulation 
in vitro and in neonatal rats.  Neuroreport  2017; 28:492-7. 
[PMID: 28430709].
20. Briones TL, Darwish H. Vitamin D mitigates age-related 
cognitive decline through the modulation of pro-inflamma-
tory state and decrease in amyloid burden.  J Neuroinflam-
mation  2012; 9:244-[PMID: 23098125].
21. Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, 
Waubant E. Vitamin D in clinically isolated syndrome: 
Molecular Vision 2019; 25:438-445 <http://www.molvis.org/molvis/v25/438> © 2019 Molecular Vision 
445
evidence for possible neuroprotection.  Eur J Neurol  2016; 23:327-32. [PMID: 26518224].
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. 
The print version of this article was created on 9 August 2019. This reflects all typographical corrections and errata to the 
article through that date. Details of any changes may be found in the online version of the article.
